Aleniglipron by Structure Therapeutics: status and timeline

Aleniglipron

Once-daily oral small-molecule GLP-1 agonist for obesity, competitive with injectable drugs.

PilotStage 3 of 5

Phase 2b: 15–16% weight loss. Phase 3 ACCOMPLISH began dosing in 2026: up to 4,700 adults in two trials.

Updated 8 Sep 2026Checked 11 Oct0 updates this week

Milestones

Next · Phase III registration trial initiation

Phase 2a ACCESS I trial2025Complete.
Phase 2 ACCESS II topline data (44 weeks)Mar 2026Complete.
Phase 2b body-composition and open-label extension data8 Sep 2026Complete.
Phase III registration trial initiationTarget Q3 2026Current milestone.

Most important updates

Upcoming

Q3 2026Phase III registration trial initiation (next)

Current obstacles

Matching injectable GLP-1 weight loss in a pillInjectable drugs achieve 15–22% weight loss. Achieving this with a small molecule requires optimization.
Managing GI side effects at high dosesGLP-1 agonism causes nausea and GI disturbance. Balancing efficacy and tolerability is key.

Physics limits

Small molecules activate GLP-1 throughout the bodyOral absorption is rapid; GLP-1 receptors on gut and brain both activate, increasing side effects vs. slow-reaching injectables.
Oral bioavailability is limited by gut absorptionDrugs must survive stomach acid and cross the intestinal barrier. Not all designs can be made absorbable.

How it works

3 parts

GLP-1 receptor agonism

Mimics a natural hormone that reduces appetite

Binds GLP-1 receptor on brain and gut, signals fullness, slows gastric emptying. Same target as injectables.

Small-molecule design

Oral absorption through the gut

Small organic molecule dissolves and is absorbed through the gut when swallowed.

Once-daily dosing

Simple daily pill regimen

Once-daily schedule may improve patient adherence vs. weekly injections.

Spec sheet

Spec	Aleniglipron
Weight loss at 180 mg dose (72 weeks)	15.3% average^R (reported)
Weight loss at 240 mg dose (72 weeks)	16.2% in completing patients^R (reported)
Dosing frequency	Once daily, oral pill^R (reported)
Discontinuation due to adverse events	Fewer than 5% across all dose groups^R (reported)

^R reported by the company

Papers & demos

1 item

8 Sep 2026demo
Phase 2b data shows 15–16% weight loss with no plateau (opens globenewswire.com)Body-composition and open-label extension data; up to 16.2% at 72 weeks.

Update log

2 updates

Tue 8 Sep

Major: Structure reports Phase 2b body-composition data and open-label extension results; no weight-loss plateau observedPressTest

Mar 2026

Major: Aleniglipron achieves up to 16% weight loss in Phase 2 ACCESS II trial; Phase III planned for Q3 2026PressTest

About Structure Therapeutics

The team behind Aleniglipron

Structure Therapeutics

Oral GLP-1 pill, aleniglipron, small molecule, GPCR modulators

Structure Therapeutics is a public biopharmaceutical company founded in 2017 and headquartered in South San Francisco. It develops oral small-molecule treatments for obesity, diabetes, and cardiopulmonary diseases, with a focus on GLP-1 and amylin receptor agonists.

Aleniglipron showed 15–16% body-weight loss in Phase 2b, competitive with injectable GLP-1s.
Public on NASDAQ (GPCR); raised ~$1.5B total equity since 2017.
Phase III registration trials planned Q3 2026 with ~4,700 patients.

structuretherapeutics.com (opens structuretherapeutics.com)Company profile →

Founded: 20179 yrs
Headquarters: United States
Status: Public
Listed: GPCR (opens google.com)NASDAQ
Valuation: $2.8Best. market capSep 2026estimate
Staff: ~144Jan 2026
Raised: $1.3B3 rounds
Last round: Private placement · $547MDec 2025
Works in: BiotechObesity & metabolism
Coverage: 1 program · 5 updateslatest 8 Sep 2026checked 10 Oct
Partners: Schrödinger (opens schrodinger.com)
People: Raymond Stevens (opens linkedin.com)CEO and Founder

Spec

Aleniglipron

Weight loss at 180 mg dose (72 weeks)

15.3% average^R (reported)

Weight loss at 240 mg dose (72 weeks)

16.2% in completing patients^R (reported)

Dosing frequency

Once daily, oral pill^R (reported)

Discontinuation due to adverse events

Fewer than 5% across all dose groups^R (reported)